openPR Logo
Press release

Benign Positional Vertigo Treatment Market Scenario Highlighting Major Drivers & Trends, 2018-2028 // key player - AstraZeneca plc., Intas Pharmaceutical Ltd., Cadila Pharmaceuticals, Pfizer Inc., Sanofi S.A.

04-10-2019 09:26 AM CET | Health & Medicine

Press release from: Fact.MR

Benign Positional Vertigo Treatment Market Scenario

The varied application of benign positional vertigo testing procedures in analyzing/tracking the inner ear and central nervous system and increasing adoption of the treatments in the routine check-ups are harnessing the growth of the Benign Positional Vertigo Treatment Market. However, lack of awareness regarding benign positional vertigo treatments is expected to restrain the growth of the benign positional vertigo treatment market.

Request TOC of this Report- https://www.factmr.com/connectus/sample?flag=T&rep_id=1292

Benign positional vertigo (BPPV) is a sensation of spinning, a form of dizziness. This sensation happens for a few minutes and stops automatically. Benign positional vertigo is related to the labyrinth system which is present inside the inner ear and is responsible for maintaining balance in the body. Sometimes, the free floating particles in the inner ear exert a force to cause benign positional vertigo symptoms. Other causes for benign positional vertigo symptoms include viral infection, nerve inflammation, complications after the ear surgery, side effects of medication and rapid head movement. Nausea, sweating, abnormal eye movements and vomiting are the common symptoms caused by benign positional vertigo. Other symptoms include visual disturbance, hearing loss, and difficulty in speaking and walking. Benign positional vertigo is treated by simple exercises such as Epley maneuver or Brandt–Daroff. Benign positional vertigo treatment is done by the Dix–Hallpike test to determine the posterior semicircular canal involvement and Roll test to check the horizontal semicircular canal involvement. Benign positional vertigo treatment is also done by medications and surgeries. Medication involved in benign positional vertigo treatment by drug class are anti-histamine, anti-cholinergic, and anti-depressant or sedative-hypnotics.

Benign Positional Vertigo Treatment Market: Drivers and Restraints

The growing number of cases of benign positional vertigo is driving the growth of the benign positional vertigo treatment market. Rapid turnaround time, lower cost of procedure over conventional methods also fuel the growth of the benign positional vertigo treatment market. Also, the varied application of benign positional vertigo testing procedures in analyzing/tracking the inner ear and central nervous system and increasing adoption of the treatments in the routine check-ups are harnessing the growth of the benign positional vertigo treatment market. However, lack of awareness regarding benign positional vertigo treatments is expected to restrain the growth of the benign positional vertigo treatment market.

Browse Full Report with TOC- https://www.factmr.com/report/1292/benign-positional-vertigo-treatment-market

According to the International Headache Society and German National Telephone Health Interview Survey 2003, 243 of 1,003 (24%) participants with moderate dizziness/vertigo had a history of vestibular vertigo and 80 (8%) fulfilled the diagnostic criteria for benign positional vertigo (56 women and 24 men; aged 28–82?years). Lifetime prevalence was 3.2% in females, 1.6% in males and 2.4% overall. Medical consultation for benign positional vertigo treatment was reported by 78% of individuals. The 1?year incidence was calculated as 0.6%. Patients usually are seen to prefer internal/general medicine (82%), otolaryngology (57%) and neurology (47%) for benign positional vertigo treatment. As per an article from the International Headache Society survey 2003, 1.1?million adults suffer from BPPV each year in Germany. Japan reported an incidence of BPPV of 0.01% and Olmsted County, Minnesota estimated the incidence of BPPV at 0.06%. Increasing number of patients visiting for benign positional vertigo treatment, and its growing demand exhibits lucrative growth opportunity for the companies operating in the market.

Benign positional vertigo treatment Market: Regional Outlook

Geographically, the global benign positional vertigo treatment market is segmented into regions viz. North America, Europe, Asia-Pacific excluding Japan, Middle East and Africa and Japan. North America & Europe regions are expected to have healthy growth in terms of revenue due to increased awareness regarding benign positional vertigo treatment as a part of the routine checkups. Besides, the lower cost of the procedure compared with other alternative treatments and low risk associated with the procedure are boosting the growth of benign positional vertigo treatment market in the regions.

Benign positional vertigo treatment Market: Key Players

Examples of some of the players identified in the benign positional vertigo treatment market include AstraZeneca plc., Intas Pharmaceutical Ltd., Cadila Pharmaceuticals, Pfizer Inc., Sanofi S.A., Medichem S.A., Liaoyuan Silver Eagle Pharmaceutical Co., Ltd., LGM Pharma, Marclabs and Sun Pharmaceutical Industries Ltd.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Request Brochure of this Report- https://www.factmr.com/connectus/sample?flag=B&rep_id=1292

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Benign Positional Vertigo Treatment Market Scenario Highlighting Major Drivers & Trends, 2018-2028 // key player - AstraZeneca plc., Intas Pharmaceutical Ltd., Cadila Pharmaceuticals, Pfizer Inc., Sanofi S.A. here

News-ID: 1696904 • Views:

More Releases from Fact.MR

Industrial Gases Market is Analyzed to Reach a Worth of US$ 185.73 billion by 2034 | FactMR Report
Industrial Gases Market is Analyzed to Reach a Worth of US$ 185.73 billion by 20 …
Revenue from the sales of industrial gases is estimated to reach US$ 110.81 billion in 2024. The global industrial gas market is forecasted to expand at a compound annual growth rate (CAGR) of 5.3% and reach a value of US$ 185.73 billion by the end of 2034. This growth trajectory reflects the rapid pace of industrialization, the expanding role of industrial gases in advanced manufacturing, and rising demand from diverse
Hydrotropes Market Expected to Reach US$ 2,827.5 Million by 2034 | FactMR Report
Hydrotropes Market Expected to Reach US$ 2,827.5 Million by 2034 | FactMR Report
The global hydrotropes market is poised for steady growth in the coming decade. The market is projected to be valued at US$ 1,703.1 million in 2024 and is expected to expand at a CAGR of 5.2%, reaching US$ 2,827.5 million by 2034. This growth reflects rising demand across multiple industries, driven by the increasing need for solubilization, formulation stability, and eco-friendly chemical solutions. Market Segmentation Overview By Functionality Hydrotropes play diverse roles in
Home Care Chemicals Market is Forecasted to Reach US$ 38.32 billion by the end of 2034 | FactMR Report
Home Care Chemicals Market is Forecasted to Reach US$ 38.32 billion by the end o …
The global home care chemical market is projected to reach a value of US$ 23.75 billion in 2024, according to a newly published study by Fact.MR. Worldwide sales of home care chemicals are expected to climb at a CAGR of 4.9% and reach US$ 38.32 billion by 2034. This steady mid-single-digit growth highlights the expanding need for cleaning and laundry products, fueled by higher standards of hygiene, innovation in formulations,
White Spirits Market is Projected to Reach US$ 11.4 billion by 2034 | FactMR Report
White Spirits Market is Projected to Reach US$ 11.4 billion by 2034 | FactMR Rep …
The global white spirit market is experiencing steady expansion as demand continues to rise across paints and coatings, industrial cleaning, degreasing processes, and solvent extraction applications. Revenue from the market is estimated at US$ 7.56 billion in 2024 and is forecasted to increase at a compound annual growth rate (CAGR) of 4.2%, reaching US$ 11.4 billion by the end of 2034. This growth is attributed to the versatility of white

All 5 Releases


More Releases for Benign

Rising Geriatric Population Drives Growth Of Benign Prostatic Hypertrophy Drugs …
The Drugs For Benign Prostatic hypertrophy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Drugs For Benign Prostatic hypertrophy Market? The drugs for benign prostatic hypertrophy market has shown strong growth, expanding from $4.28 billion in 2024 to $4.58
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market? The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be? In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market? The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market? The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be? In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.